Aurobindo Pharma's Bupropion Hydrochloride ANDA216051 Receives AP Status
Aurobindo Pharma's ANDA216051 for Bupropion Hydrochloride has received Abbreviated Approval (AP) status from the FDA.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Depression
Company: Aurobindo Pharma
Asset: Aurobindo
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Aurobindo Pharma
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's Abbreviated Approval of Aurobindo Pharma's Bupropion Hydrochloride positions the company to increase competition in the neurology and depression therapeutic areas. This could impact pricing and market share for existing players in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the launch timeline and market response to Aurobindo's Bupropion Hydrochloride product.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.